HanchorBio, a clinical-stage biotech company focusing on immunotherapies for oncology and autoimmune diseases, signed a collaboration agreement to support the development and manufacturing of multiple next-generation bi- and multi-functional fusion programs from HanchorBio’s pipeline.
![HanchorBio Chairman Scott Liu (left) and WuXi Biologics CEO Chris Chen after signing the strategic partnership agreement. [HanchorBio]](https://www.genengnews.com/wp-content/uploads/2026/01/Strategic-Partnership-Between-Hanchorbio-and-WuXi-Biologics-1-2048x1152-1-300x169.jpg)
Chris Chen, CEO of WuXi Biologics, says the company will provide integrated, end-to-end biologics development and manufacturing services, including cell line development, process and bioassay development, drug product formulation development, and GMP manufacturing. The collaboration is designed to accelerate clinical translation and support scalable global development and manufacturing of HanchorBio’s fusion protein portfolio derived from its Fc-Based Designer Biologics (FBDB™) platform.
By leveraging WuXi Biologics expertise in complex biologics and its quality systems, HanchorBio aims to shorten development timelines and maintain flexibility across multiple clinical programs, according to Scott Liu, founder, chairman, and CEO of HanchorBio, who adds that “this partnership with WuXi Biologics strengthens our ability to translate platform-driven innovation into high-quality clinical and commercial assets.”
